{"analyses":[{"ciLowerLimit":"1.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"13.4","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0155","pValueComment":"Model included treatment+visit+treatment by visit interaction+stratification factor for region (U.S. versus non-U.S.) and tumor location (lower limb/all other) based on IRT+VAS baseline value.","paramType":"LS Mean Difference","paramValue":"7.4","statisticalMethod":"Mixed model repeated measures"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.35","value":"13.5"},{"groupId":"OG001","spread":"2.85","value":"6.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"The EQ-VAS is a standardized tool for measuring overall health. EQ-VAS recorded the participant's self-rated health on a vertical VAS scale ranging from a minimum of 0 (worst imaginable health state) to a maximum of 100 (best imaginable health state). Higher scores indicated better health state.","dispersionType":"Standard Error","groups":[{"description":"Participants received 30 mg BIW vimseltinib for 24 weeks.","id":"OG000","title":"Vimseltinib"},{"description":"Participants received matching placebo BIW for 24 weeks.","id":"OG001","title":"Placebo"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The ITT Set consisted of participants who were randomized to a study treatment regimen. Here, \"Overall Number of Participants Analyzed\" is the number of participants evaluable for this outcome measure at the specified time point.","reportingStatus":"POSTED","timeFrame":"Baseline to Week 25 (Cycle 7, Day 1)","title":"Change From Baseline in EuroQoL Visual Analogue Scale (EQ-VAS) at Week 25","type":"SECONDARY","unitOfMeasure":"score on a scale"}